Search Result

Pathways Recommended:	MAPK/ERK Pathway

Results for "

mevalonic acid pathway

" in MedChemExpress (MCE) Product Catalog:

標的別:	Calcineurin (1) Drug Derivative (1) Drug Isomer (1) Endogenous Metabolite (12) HMG-CoA Reductase (HMGCR) (1) Isotope-Labeled Compounds (3) Ras (1) Reference Standards (2)
研究分野別:	Cancer (2) Cardiovascular Disease (4) Inflammation/Immunology (6) Metabolic Disease (12) Neurological Disease (4)

阻害剤およびアゴニスト

天然物

同位体標識化合物

Targets Recommended: Tissue Factor Pathway Inhibitor (TFPI)

製品番号	製品名	Target	研究分野	構造式

HY-113071A

Mevalonic acid lithium salt 5+ Cited Publications MVA lithium salt	Endogenous Metabolite	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Mevalonic acid (MVA) lithium salt is a precursor substance of the mevalonate pathway, which is essential for cell growth and proliferation. Mevalonic acid lithium salt is effective in inhibiting Simvastatin (HY-17502)-induced decrease in C2C12 cell viability in vitro. Mevalonic acid lithium salt can be used in studies of myopathy and heart failure .

HY-N9474

Mevalonic acid 5-pyrophosphate tetralithium 5-Diphosphomevalonic acid tetralithium; mevalonic acid 5-diphosphate tetralithium	Endogenous Metabolite	Others
Mevalonic acid 5-pyrophosphate (5-Diphosphomevalonic acid) tetralithium is an endogenous metabolite of the mevalonate pathway .

HY-107855

DL-Mevalonolactone 1 Publications Verification (±)-Mevalonolactone; Mevalolactone	Endogenous Metabolite	Metabolic Disease Inflammation/Immunology
DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy . DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling ^[2][4].

HY-113071

Mevalonic acid MVA	Endogenous Metabolite	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Mevalonic acid (MVA) is a precursor substance of the mevalonate pathway, which is essential for cell growth and proliferation. Mevalonic acid is effective in inhibiting Simvastatin (HY-17502)-induced decrease in C2C12 cell viability in vitro. Mevalonic acid can be used in studies of myopathy and heart failure .

HY-135700

Mevalonolactone	Calcineurin Ras HMG-CoA Reductase (HMGCR)	Metabolic Disease Inflammation/Immunology
Mevalonolactone is an intermediate metabolite in the eukaryotic mevalonate pathway, serving as the stable δ-lactone form of mevalonate with oral activity. Mevalonolactone exhibits binding affinity for ZNF384 (K_a = 12.6 μM) and inhibitory activity against aconitase (aconitase). Mevalonolactone promotes the nuclear localization of ZNF384 and enhances its binding to the GGPPS promoter. Mevalonolactone induces insulin resistance, disrupts glucose and lipid metabolism, enhances the isoprenylation of K-Ras, and inhibits the activation of the insulin signaling pathway. Mevalonolactone inhibits polypeptide synthesis of HMG-CoA reductase in isolated rat hepatocytes, promotes its degradation, and reduces its enzymatic activity. Mevalonolactone impairs mitochondrial function in rat brains. Mevalonolactone promotes the development of metabolically unhealthy obesity. Mevalonolactone can be used in research related to metabolically abnormal obesity, mevalonic aciduria, HMGCR-related limb-girdle myopathy, and statin-induced myopathy .

HY-107855S

DL-Mevalonolactone-d7 (±)-Mevalonolactone-d₇; Mevalolactone-d₇	Endogenous Metabolite	Metabolic Disease
DL-Mevalonolactone-d₇ is the deuterium labeled DL-Mevalonolactone. DL-Mevalonolactone ((±)-Mevalonolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone (Mevalonolactone) decreases mitochondrial membrane potential (?Ψm), NAD(P)H content and the capacity to retain Ca2+ in the brain, besides inducing mitochondrial swelling .

HY-113071C

(S)-Mevalonic acid (S)-MVA	Endogenous Metabolite	Cardiovascular Disease Neurological Disease Metabolic Disease
(S)-Mevalonic acid is the isomer of Mevalonic acid (HY-113071). Mevalonic acid ((S)-DCIT) is a precursor substance of the mevalonate pathway, which is essential for cell growth and proliferation. Mevalonic acid is effective in inhibiting Simvastatin (HY-17502)-induced decrease in C2C12 cell viability in vitro. Mevalonic acid can be used in studies of myopathy and heart failure .

HY-113071AR

Mevalonic acid lithium salt (Standard) MVA lithium salt (Standard)	Reference Standards Endogenous Metabolite	Cardiovascular Disease Neurological Disease Metabolic Disease
Mevalonic acid lithium salt (Standard) is the analytical standard of Mevalonic acid lithium salt. This product is intended for research and analytical applications. Mevalonic acid (MVA) lithium salt is a precursor substance of the mevalonate pathway, which is essential for cell growth and proliferation. Mevalonic acid lithium salt is effective in inhibiting Simvastatin (HY-17502)-induced decrease in C2C12 cell viability in vitro. Mevalonic acid lithium salt can be used in studies of myopathy and heart failure .

HY-107855S1

DL-Mevalonolactone-d3 (±)-Mevalonolactone-d₃; Mevalolactone-d₃	Endogenous Metabolite	Metabolic Disease
DL-Mevalonolactone-d₃ is the deuterium labeled DL-Mevalonolactone . DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone (Mevalonolactone) decreases mitochondrial membrane potential ( Ψm), NAD(P)H content and the capacity to retain Ca2+ in the brain, besides inducing mitochondrial swelling .

HY-107855R

DL-Mevalonolactone (Standard) (±)-Mevalonolactone (Standard); Mevalolactone (Standard)	Endogenous Metabolite Reference Standards	Metabolic Disease Inflammation/Immunology
DL-Mevalonolactone (Standard) is the analytical standard of DL-Mevalonolactone. This product is intended for research and analytical applications. DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy . DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling .

HY-W725424

(R)-Mevalonic acid sodium (R)-MVA sodium	Drug Isomer	Others
(R) -Mevalonic acid ( (R) -MVA) sodium is an isomer of Mevalonic acid (HY-113071) . Mevalonic acid (MVA) is a precursor substance in the mevalonate pathway and is crucial for cell growth and proliferation.

HY-N19716

Austamide	Drug Derivative	Others
Austamide is an indole alkaloid found in cultures of Aspergillus ustus. Austamide undergoes biosynthesis via the classical mevalonate pathway with nonface-selective reverse prenylation of its indole ring .

HY-107855S2

DL-Mevalonolactone-13C (±)-Mevalonolactone-¹³C; Mevalolactone-¹³C	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease Inflammation/Immunology
DL-Mevalonolactone- ¹³C ((±)-Mevalonolactone- ¹³C) is the ¹³C-labeled DL-Mevalonolactone (HY-107855). DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy. DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling.

HY-107855S4

DL-Mevalonolactone-13C2 (±)-Mevalonolactone-¹³C₂; Mevalolactone-¹³C₂	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease Inflammation/Immunology
DL-Mevalonolactone- ¹³C₂ ((±)-Mevalonolactone- ¹³C₂) is the ¹³C-labeled DL-Mevalonolactone (HY-107855). DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy . DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling ^[2][4].

HY-W752587

DL-Mevalonolactone-d4 (±)-Mevalonolactone-d₄; Mevalolactone-d₄	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease Inflammation/Immunology
DL-Mevalonolactone-d₄ ( (±)-Mevalonolactone-d₄) is the deuterium labeled DL-Mevalonolactone (HY-107855). DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy . DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling .

製品番号	製品名	Category	Target	構造式

HY-113071A

Mevalonic acid lithium salt 5+ Cited Publications MVA lithium salt	Classification of Application Fields Ketones, Aldehydes, Acids Other Diseases Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
Mevalonic acid (MVA) lithium salt is a precursor substance of the mevalonate pathway, which is essential for cell growth and proliferation. Mevalonic acid lithium salt is effective in inhibiting Simvastatin (HY-17502)-induced decrease in C2C12 cell viability in vitro. Mevalonic acid lithium salt can be used in studies of myopathy and heart failure .

HY-N9474

Mevalonic acid 5-pyrophosphate tetralithium 5-Diphosphomevalonic acid tetralithium; mevalonic acid 5-diphosphate tetralithium	Classification of Application Fields Ketones, Aldehydes, Acids Other Diseases Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
Mevalonic acid 5-pyrophosphate (5-Diphosphomevalonic acid) tetralithium is an endogenous metabolite of the mevalonate pathway .

HY-107855

DL-Mevalonolactone 1 Publications Verification (±)-Mevalonolactone; Mevalolactone	天然物 Classification of Application Fields Metabolic Disease Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	Endogenous Metabolite
DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy . DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling ^[2][4].

HY-113071

Mevalonic acid MVA	Human Gut Microbiota Metabolites Immune System Disorder Classification of Application Fields Ketones, Aldehydes, Acids Disease markers Other Diseases Endocrine diseases Nervous System Disorder Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Mevalonic acid (MVA) is a precursor substance of the mevalonate pathway, which is essential for cell growth and proliferation. Mevalonic acid is effective in inhibiting Simvastatin (HY-17502)-induced decrease in C2C12 cell viability in vitro. Mevalonic acid can be used in studies of myopathy and heart failure .

HY-135700

Mevalonolactone	Structural Classification Microorganisms Other Phenylpropanoids Phenylpropanoids Source Classification	Calcineurin Ras HMG-CoA Reductase (HMGCR)
Mevalonolactone is an intermediate metabolite in the eukaryotic mevalonate pathway, serving as the stable δ-lactone form of mevalonate with oral activity. Mevalonolactone exhibits binding affinity for ZNF384 (K_a = 12.6 μM) and inhibitory activity against aconitase (aconitase). Mevalonolactone promotes the nuclear localization of ZNF384 and enhances its binding to the GGPPS promoter. Mevalonolactone induces insulin resistance, disrupts glucose and lipid metabolism, enhances the isoprenylation of K-Ras, and inhibits the activation of the insulin signaling pathway. Mevalonolactone inhibits polypeptide synthesis of HMG-CoA reductase in isolated rat hepatocytes, promotes its degradation, and reduces its enzymatic activity. Mevalonolactone impairs mitochondrial function in rat brains. Mevalonolactone promotes the development of metabolically unhealthy obesity. Mevalonolactone can be used in research related to metabolically abnormal obesity, mevalonic aciduria, HMGCR-related limb-girdle myopathy, and statin-induced myopathy .

HY-113071AR

Mevalonic acid lithium salt (Standard) MVA lithium salt (Standard)	Structural Classification Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
Mevalonic acid lithium salt (Standard) is the analytical standard of Mevalonic acid lithium salt. This product is intended for research and analytical applications. Mevalonic acid (MVA) lithium salt is a precursor substance of the mevalonate pathway, which is essential for cell growth and proliferation. Mevalonic acid lithium salt is effective in inhibiting Simvastatin (HY-17502)-induced decrease in C2C12 cell viability in vitro. Mevalonic acid lithium salt can be used in studies of myopathy and heart failure .

HY-107855R

DL-Mevalonolactone (Standard) (±)-Mevalonolactone (Standard); Mevalolactone (Standard)	Structural Classification 天然物 Endogenous metabolite Source Classification	Endogenous Metabolite Reference Standards
DL-Mevalonolactone (Standard) is the analytical standard of DL-Mevalonolactone. This product is intended for research and analytical applications. DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy . DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling .

HY-N19716

Austamide	Structural Classification Alkaloids Microorganisms Indole Alkaloids Source Classification	Drug Derivative
Austamide is an indole alkaloid found in cultures of Aspergillus ustus. Austamide undergoes biosynthesis via the classical mevalonate pathway with nonface-selective reverse prenylation of its indole ring .

製品番号	製品名	構造式

HY-107855S

DL-Mevalonolactone-d7
DL-Mevalonolactone-d₇ is the deuterium labeled DL-Mevalonolactone. DL-Mevalonolactone ((±)-Mevalonolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone (Mevalonolactone) decreases mitochondrial membrane potential (?Ψm), NAD(P)H content and the capacity to retain Ca2+ in the brain, besides inducing mitochondrial swelling .

HY-107855S1

DL-Mevalonolactone-d3
DL-Mevalonolactone-d₃ is the deuterium labeled DL-Mevalonolactone . DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone (Mevalonolactone) decreases mitochondrial membrane potential ( Ψm), NAD(P)H content and the capacity to retain Ca2+ in the brain, besides inducing mitochondrial swelling .

DL-Mevalonolactone-d3

DL-Mevalonolactone-d₃ is the deuterium labeled DL-Mevalonolactone . DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone (Mevalonolactone) decreases mitochondrial membrane potential ( Ψm), NAD(P)H content and the capacity to retain Ca2+ in the brain, besides inducing mitochondrial swelling .

HY-107855S2

DL-Mevalonolactone-13C
DL-Mevalonolactone- ¹³C ((±)-Mevalonolactone- ¹³C) is the ¹³C-labeled DL-Mevalonolactone (HY-107855). DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy. DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling.

DL-Mevalonolactone-13C

DL-Mevalonolactone- ¹³C ((±)-Mevalonolactone- ¹³C) is the ¹³C-labeled DL-Mevalonolactone (HY-107855). DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy. DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling.

HY-107855S4

DL-Mevalonolactone-13C2
DL-Mevalonolactone- ¹³C₂ ((±)-Mevalonolactone- ¹³C₂) is the ¹³C-labeled DL-Mevalonolactone (HY-107855). DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy . DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling ^[2][4].

DL-Mevalonolactone-13C2

DL-Mevalonolactone- ¹³C₂ ((±)-Mevalonolactone- ¹³C₂) is the ¹³C-labeled DL-Mevalonolactone (HY-107855). DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy . DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling ^[2][4].

HY-W752587

DL-Mevalonolactone-d4
DL-Mevalonolactone-d₄ ( (±)-Mevalonolactone-d₄) is the deuterium labeled DL-Mevalonolactone (HY-107855). DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy . DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling .

DL-Mevalonolactone-d4

DL-Mevalonolactone-d₄ ( (±)-Mevalonolactone-d₄) is the deuterium labeled DL-Mevalonolactone (HY-107855). DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy . DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling .

オンラインお問い合わせ

入力情報は安全に管理されます. ※ 必須入力項目.

日本の代理先をお選びくださいナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
タイトル			国或いは地域 *
お名前 *			組纖名 *
デパートメント *
メールアドレス *			製品名 *
製品番号			カスタマ需要量 *
電話番号 *
必ず会社名を記載ください。個人への返信は行いません。
備考

バルクお問い合わせ

Inquiry Information

製品名:
製品番号:
数量:
MCE 日本正規代理店:

お名前
メール *

	Sorry, but the email address you supplied was invalid.